Objective: To evaluate the predictive value of the platelet-albumin-bilirubin (PALBI) score for hepatic failure after transarterial chemoembolization (TACE) in patients with non-small hepatocellular carcinoma (HCC) (tumor diameter > 5 cm).
Methods: A retrospective study included 577 non-small HCC patients who underwent TACE between January 2018 and December 2024. Patients were stratified by PALBI grade (Grade 1: ≤-2.53; Grade 2: > -2.53 to ≤-2.09; Grade 3: > -2.09). Hepatic failure was defined and graded (A-C) according to ISGLS criteria. The predictive efficacy of PALBI, ALBI, and Child-Pugh scores was compared using ROC curves.
Results: Hepatic failure occurred in 28.2% (163/577) of patients (Grade A: 22.0%; B: 4.6%; C: 1.5%). Hepatic failure incidence significantly increased with PALBI grade: 10.31% (Grade 1), 27.83% (Grade 2), and 78.95% (Grade 3) (p < 0.001). PALBI demonstrated superior predictive efficacy (AUC = 0.746) compared to ALBI (AUC = 0.702, p = 0.004) and Child-Pugh (AUC = 0.706, p = 0.075). Multivariate analysis identified ascites, AST, and total bilirubin as independent risk factors for hepatic failure (p < 0.05).
Conclusion: The PALBI score is an effective tool for predicting hepatic failure after TACE in non-small HCC patients. PALBI Grade 3 indicates high risk (78.95%), suggesting preoperative liver protection therapy before TACE. PALBI outperforms ALBI and Child-Pugh scores in risk stratification.
目的:探讨血小板-白蛋白-胆红素(PALBI)评分对非小肝细胞癌(HCC)患者经动脉化疗栓塞(TACE)后肝功能衰竭的预测价值。方法:一项回顾性研究包括577例在2018年1月至2024年12月期间接受TACE治疗的非小肝癌患者。患者按PALBI分级进行分层(1级:≤-2.53;2级:> -2.53至≤-2.09;3级:> -2.09)。根据ISGLS标准定义肝衰竭并分级(A-C)。采用ROC曲线比较PALBI、ALBI和Child-Pugh评分的预测效果。结果:28.2%(163/577)的患者发生肝功能衰竭(A级:22.0%,B级:4.6%,C级:1.5%)。肝功能衰竭发生率随PALBI分级显著增加:10.31%(1级)、27.83%(2级)和78.95%(3级)(p p = 0.004)和Child-Pugh (AUC = 0.706, p = 0.075)。多因素分析发现,腹水、AST和总胆红素是肝衰竭的独立危险因素(p)。结论:PALBI评分是预测非小肝癌患者TACE术后肝衰竭的有效工具。PALBI 3级提示高危(78.95%),建议在TACE前进行术前肝保护治疗。PALBI在风险分层方面优于ALBI和Child-Pugh评分。
{"title":"The platelet-albumin-bilirubin score in predicting hepatic failure after TACE for non-small hepatocellular carcinoma.","authors":"Wenxiang Liang, Hankun Yuan, Jiajie Zhou, Sizong Chen, Heqian Huang, Liang Xu, Yufei Ma, Yuan Lu, Zongjiang Luo, Libai Lu, Jiasheng Ma, Zhenrong Zhao, Jianchu Wang","doi":"10.1080/00325481.2025.2587342","DOIUrl":"10.1080/00325481.2025.2587342","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the predictive value of the platelet-albumin-bilirubin (PALBI) score for hepatic failure after transarterial chemoembolization (TACE) in patients with non-small hepatocellular carcinoma (HCC) (tumor diameter > 5 cm).</p><p><strong>Methods: </strong>A retrospective study included 577 non-small HCC patients who underwent TACE between January 2018 and December 2024. Patients were stratified by PALBI grade (Grade 1: ≤-2.53; Grade 2: > -2.53 to ≤-2.09; Grade 3: > -2.09). Hepatic failure was defined and graded (A-C) according to ISGLS criteria. The predictive efficacy of PALBI, ALBI, and Child-Pugh scores was compared using ROC curves.</p><p><strong>Results: </strong>Hepatic failure occurred in 28.2% (163/577) of patients (Grade A: 22.0%; B: 4.6%; C: 1.5%). Hepatic failure incidence significantly increased with PALBI grade: 10.31% (Grade 1), 27.83% (Grade 2), and 78.95% (Grade 3) (<i>p</i> < 0.001). PALBI demonstrated superior predictive efficacy (AUC = 0.746) compared to ALBI (AUC = 0.702, <i>p</i> = 0.004) and Child-Pugh (AUC = 0.706, <i>p</i> = 0.075). Multivariate analysis identified ascites, AST, and total bilirubin as independent risk factors for hepatic failure (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>The PALBI score is an effective tool for predicting hepatic failure after TACE in non-small HCC patients. PALBI Grade 3 indicates high risk (78.95%), suggesting preoperative liver protection therapy before TACE. PALBI outperforms ALBI and Child-Pugh scores in risk stratification.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"799-806"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145508582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-11-18DOI: 10.1080/00325481.2025.2587365
Yuan Wang, Mengjin Wang, Jingwei Sun
Objective: Severe pneumonia is typically characterized by severe pulmonary inflammatory responses. This study evaluated the predictive value of D-dimer (DD) and neutrophil-to-lymphocyte ratio (NLR) for disease severity in children with severe pneumonia.
Methods: Children with severe pneumonia (280 cases) were enrolled and divided into the critical and non-critical groups based on the pediatric critical illness score (PCIS). Clinical data were collected at patients' initial admission. Correlations of DD and NLR with the PCIS, their predictive value and the independent predictors for disease severity in children with severe pneumonia were assessed by Spearman test, receiver operating characteristic curve and multivariate logistic regression. Outcomes were determined as per the 28-day disease progression.
Results: The critical group showed higher DD and NLR than the non-critical group. DD and NLR negatively correlated with the PCIS. Children in the higher DD quartile group showed higher systolic blood pressure (SBP), NLR and procalcitonin, and lower platelet and PCIS. Children in the higher NLR quartile group had higher SBP, DD and procalcitonin, and platelet and lower PCIS. Areas under the curve to predict severe pneumonia severity were 0.805, 0.883 and 0.918 for DD, NLR and their combination, suggesting superior diagnostic value of their combination for disease severity. The critical group (59.05%) had higher 28-day poor outcomes of pneumonia than the non-critical group (18.29%). DD and NLR were independent risk factors for the disease severity in severe pneumonia children.
Conclusion: Elevated DD and NLR have certain predictive value for disease severity and poor prognosis in severe pneumonia children.
{"title":"The predictive value of D-dimer and neutrophil-to-lymphocyte ratio for the severity of severe pneumonia in children.","authors":"Yuan Wang, Mengjin Wang, Jingwei Sun","doi":"10.1080/00325481.2025.2587365","DOIUrl":"10.1080/00325481.2025.2587365","url":null,"abstract":"<p><strong>Objective: </strong>Severe pneumonia is typically characterized by severe pulmonary inflammatory responses. This study evaluated the predictive value of D-dimer (DD) and neutrophil-to-lymphocyte ratio (NLR) for disease severity in children with severe pneumonia.</p><p><strong>Methods: </strong>Children with severe pneumonia (280 cases) were enrolled and divided into the critical and non-critical groups based on the pediatric critical illness score (PCIS). Clinical data were collected at patients' initial admission. Correlations of DD and NLR with the PCIS, their predictive value and the independent predictors for disease severity in children with severe pneumonia were assessed by Spearman test, receiver operating characteristic curve and multivariate logistic regression. Outcomes were determined as per the 28-day disease progression.</p><p><strong>Results: </strong>The critical group showed higher DD and NLR than the non-critical group. DD and NLR negatively correlated with the PCIS. Children in the higher DD quartile group showed higher systolic blood pressure (SBP), NLR and procalcitonin, and lower platelet and PCIS. Children in the higher NLR quartile group had higher SBP, DD and procalcitonin, and platelet and lower PCIS. Areas under the curve to predict severe pneumonia severity were 0.805, 0.883 and 0.918 for DD, NLR and their combination, suggesting superior diagnostic value of their combination for disease severity. The critical group (59.05%) had higher 28-day poor outcomes of pneumonia than the non-critical group (18.29%). DD and NLR were independent risk factors for the disease severity in severe pneumonia children.</p><p><strong>Conclusion: </strong>Elevated DD and NLR have certain predictive value for disease severity and poor prognosis in severe pneumonia children.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"790-798"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145544737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-11-21DOI: 10.1080/00325481.2025.2592356
Ahmet Serkan Özcan, Raziye Merve Yaradilmiş, Bilge Akkaya, Fatma Şule Erdem, Orkun Aydin, Betül Öztürk, Ali Güngör, Nilden Tuygun
Objectives: Serotonin syndrome (SS) is a life-threatening emergency that develops as a result of increased serotonin amount or activity in the synaptic cleft. The present study aimed to determine the clinical findings in serotonergic drug intoxications in children that may alert clinicians about the development of SS.
Methods: The patients aged between 1 to 18 years, who were admitted to the pediatric emergency department (PED) because of drug intoxications between September 2022 and August 2024, were analyzed retrospectively. Patients with a history of taking one or more serotonergic drugs were included in the study. Patients were divided into two groups: SS and without SS. The sensitivity, specificity, negative and positive predictive value (PPV) of the Hunter's criteria and SS-related symptoms were evaluated.
Results: A total of 162 patients were included in the study. SS developed in 25 (15.4%) of the patients. SS developed in 23 (21.1%) of 109 patients receiving SSRI group drugs, while SS developed in two (4.8%) of 42 patients receiving non-SSRI group drugs (p = 0.015). Nineteen (76%) of the patients diagnosed with serotonin syndrome were also diagnosed with SS according to Hunter's criteria, and the sensitivity and specificity of Hunter's criteria in the diagnosis of SS in pediatric patients were 76% and 100%, respectively. The specificity and PPV were 100% for spontaneous clonus, inducible clonus, ocular clonus, hyperreflexia, and hyperthermia in the diagnosis of serotonin syndrome. The symptoms with the highest sensitivity were mydriasis (76%) and tremor (64%). All patients with serotonin syndrome were treated with cyproheptadine, and clinical findings improved.
Conclusion: SS developed in 15.4% of patients with serotonergic drug intoxication, and the sensitivity of Hunter's criteria for the diagnosis of SS was 76%. The combined use of Hunter's criteria and clinician decision in the diagnosis of childhood SS may be more useful.
{"title":"Evaluation of clinical findings in predicting the development of serotonin syndrome: can the Hunter's criteria be used in children?","authors":"Ahmet Serkan Özcan, Raziye Merve Yaradilmiş, Bilge Akkaya, Fatma Şule Erdem, Orkun Aydin, Betül Öztürk, Ali Güngör, Nilden Tuygun","doi":"10.1080/00325481.2025.2592356","DOIUrl":"10.1080/00325481.2025.2592356","url":null,"abstract":"<p><strong>Objectives: </strong>Serotonin syndrome (SS) is a life-threatening emergency that develops as a result of increased serotonin amount or activity in the synaptic cleft. The present study aimed to determine the clinical findings in serotonergic drug intoxications in children that may alert clinicians about the development of SS.</p><p><strong>Methods: </strong>The patients aged between 1 to 18 years, who were admitted to the pediatric emergency department (PED) because of drug intoxications between September 2022 and August 2024, were analyzed retrospectively. Patients with a history of taking one or more serotonergic drugs were included in the study. Patients were divided into two groups: SS and without SS. The sensitivity, specificity, negative and positive predictive value (PPV) of the Hunter's criteria and SS-related symptoms were evaluated.</p><p><strong>Results: </strong>A total of 162 patients were included in the study. SS developed in 25 (15.4%) of the patients. SS developed in 23 (21.1%) of 109 patients receiving SSRI group drugs, while SS developed in two (4.8%) of 42 patients receiving non-SSRI group drugs (<i>p</i> = 0.015). Nineteen (76%) of the patients diagnosed with serotonin syndrome were also diagnosed with SS according to Hunter's criteria, and the sensitivity and specificity of Hunter's criteria in the diagnosis of SS in pediatric patients were 76% and 100%, respectively. The specificity and PPV were 100% for spontaneous clonus, inducible clonus, ocular clonus, hyperreflexia, and hyperthermia in the diagnosis of serotonin syndrome. The symptoms with the highest sensitivity were mydriasis (76%) and tremor (64%). All patients with serotonin syndrome were treated with cyproheptadine, and clinical findings improved.</p><p><strong>Conclusion: </strong>SS developed in 15.4% of patients with serotonergic drug intoxication, and the sensitivity of Hunter's criteria for the diagnosis of SS was 76%. The combined use of Hunter's criteria and clinician decision in the diagnosis of childhood SS may be more useful.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"807-813"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145566913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-12-21DOI: 10.1080/00325481.2025.2603034
M Thomas Bateman, Stephen Brunton, Wendy L Wright
Objectives: For many decades, guaifenesin and dextromethorphan have been two of the most well-established and commonly used nonprescription medications to manage cough and cold symptoms. A single source that summarizes the clinical data supporting the use of guaifenesin and dextromethorphan as self-care treatment options in cough and cold could assist healthcare professionals (HCPs) in making informed recommendations to patients. The objective of this narrative review is to discuss the benefits of guaifenesin and dextromethorphan for the management of cough and mucus-related cold symptoms in adults by examining published data on the effectiveness and safety of the products containing these ingredients.
Methods: Literature searches were performed on PubMed, Embase, and MEDLINE to identify randomized, controlled studies comparing guaifenesin or dextromethorphan treatment with placebo control in adults with cough and cold (mucus) symptoms. Of 36 guaifenesin and 53 dextromethorphan clinical studies initially identified by the literature search, 13 guaifenesin and 19 dextromethorphan publications met the predefined inclusion criteria. Additional studies were identified during manuscript development by reviewing the citations of included articles, for a total of 17 guaifenesin and 21 dextromethorphan publications.
Results: Data from studies of guaifenesin and dextromethorphan either used alone or combined with other active ingredients showed statistically significant improvements compared with placebo control in sputum looseness/adhesiveness and reductions in cough frequency/severity, respectively. A small number of studies did not show significant improvements with study drug compared with placebo control. Conflicting data may originate from differences in study design, patient enrollment, and a relatively high placebo control effect across studies.
Conclusion: The data reviewed in this article support the importance of guaifenesin and dextromethorphan in the armamentarium of effective nonprescription treatment options for cough and mucus-related cold symptoms.
{"title":"Guaifenesin and dextromethorphan for management of cough and mucus-related cold symptoms in adults: a narrative literature review.","authors":"M Thomas Bateman, Stephen Brunton, Wendy L Wright","doi":"10.1080/00325481.2025.2603034","DOIUrl":"10.1080/00325481.2025.2603034","url":null,"abstract":"<p><strong>Objectives: </strong>For many decades, guaifenesin and dextromethorphan have been two of the most well-established and commonly used nonprescription medications to manage cough and cold symptoms. A single source that summarizes the clinical data supporting the use of guaifenesin and dextromethorphan as self-care treatment options in cough and cold could assist healthcare professionals (HCPs) in making informed recommendations to patients. The objective of this narrative review is to discuss the benefits of guaifenesin and dextromethorphan for the management of cough and mucus-related cold symptoms in adults by examining published data on the effectiveness and safety of the products containing these ingredients.</p><p><strong>Methods: </strong>Literature searches were performed on PubMed, Embase, and MEDLINE to identify randomized, controlled studies comparing guaifenesin or dextromethorphan treatment with placebo control in adults with cough and cold (mucus) symptoms. Of 36 guaifenesin and 53 dextromethorphan clinical studies initially identified by the literature search, 13 guaifenesin and 19 dextromethorphan publications met the predefined inclusion criteria. Additional studies were identified during manuscript development by reviewing the citations of included articles, for a total of 17 guaifenesin and 21 dextromethorphan publications.</p><p><strong>Results: </strong>Data from studies of guaifenesin and dextromethorphan either used alone or combined with other active ingredients showed statistically significant improvements compared with placebo control in sputum looseness/adhesiveness and reductions in cough frequency/severity, respectively. A small number of studies did not show significant improvements with study drug compared with placebo control. Conflicting data may originate from differences in study design, patient enrollment, and a relatively high placebo control effect across studies.</p><p><strong>Conclusion: </strong>The data reviewed in this article support the importance of guaifenesin and dextromethorphan in the armamentarium of effective nonprescription treatment options for cough and mucus-related cold symptoms.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"741-755"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145807036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2026-01-08DOI: 10.1080/00325481.2025.2609392
Charles M Morin, Alex Desautels, Dinesh Kumar, Kate Pinner, Barbara Ramos, Margaret Moline
Objectives: To review the efficacy of lemborexant (LEM), a dual orexin-receptor antagonist approved in multiple countries for treatment of insomnia in adults, by assessing the consistency of the available LEM objective and subjective evidence.
Methods: Data from 2 pivotal phase 3, randomized, double-blind, parallel-group, placebo (PBO)-controlled studies are reviewed. Study 304 (1-month) and Study 303 (12-months; only first 6 months included here) evaluated the efficacy/safety of LEM 5 mg (LEM5) and LEM 10 mg (LEM10) in adults with insomnia disorder. Objective sleep onset (latency to persistent sleep [LPS]) and sleep maintenance (wake after sleep onset [WASO] and total sleep time [TST]) were assessed with polysomnography in Study 304. Subjective sleep onset latency (sSOL) and sleep maintenance (sWASO and sTST) were assessed with sleep diaries in both studies. Other patient-reported efficacy measures included Insomnia Severity Index-total score (ISI-TS), ISI-daytime functioning (ISI-DF), Fatigue Severity Scale (FSS), and Patient Global Impression-Insomnia (PGI-I).
Results: Compared with PBO, significantly larger decreases (improvements) from baseline in LPS, sSOL, WASO, and sWASO and significantly larger increases (improvements) from baseline in TST and sTST were observed within the first week of LEM treatment (as early as within the first 1-2 nights) and were sustained throughout the treatment period (1-6 months) (all p < 0.05, except for sWASO at Month 1). These improvements aligned with significantly larger decreases (improvements) from baseline in ISI-TS, ISI-DF, and PGI-I (all p < 0.05). Significantly larger decreases (improvement) from baseline in FSS scores were observed at 3 and 6 months (both p < 0.05).
Conclusion: LEM showed concordance in its ability to improve objective and subjective measures of nighttime sleep, as well as daytime functioning and patient perception of nighttime sleep. These findings demonstrate that LEM is effective both objectively and from the patient's perspective, supporting LEM as a valuable treatment option for adults with insomnia.
目的:通过评估现有LEM客观和主观证据的一致性,回顾lemborexant (LEM)的疗效,LEM是一种双重食欲素受体拮抗剂,已在多个国家批准用于治疗成人失眠。方法:回顾了2个关键的3期、随机、双盲、平行组、安慰剂(PBO)对照研究的数据。研究304(1个月)和研究303(12个月,仅包括前6个月)评估了莱姆5mg (LEM5)和莱姆10mg (LEM10)对成人失眠障碍的疗效/安全性。目的:研究304采用多导睡眠图评估睡眠开始(持续睡眠潜伏期[LPS])和睡眠维持(睡眠后醒来[WASO]和总睡眠时间[TST])。主观睡眠发作潜伏期(sSOL)和睡眠维持时间(sWASO和sTST)均采用睡眠日记进行评估。其他患者报告的疗效测量包括失眠严重程度指数-总分(ISI-TS), isi -日间功能(ISI-DF),疲劳严重程度量表(FSS)和患者整体印象-失眠(gi - i)。结果:与PBO相比,LPS、sSOL、WASO和sWASO较基线显著下降(改善),TST和sTST较基线显著增加(改善)在LEM治疗的第一周内(早在前1-2晚),并持续整个治疗期间(1-6个月)(均p p p p)。LEM在改善夜间睡眠的客观和主观测量,以及白天功能和患者夜间睡眠感知方面表现出一致性。这些研究结果表明,无论从客观上还是从患者的角度来看,LEM都是有效的,支持LEM作为成年人失眠的有价值的治疗选择。
{"title":"Consistency of objective and subjective evidence for the efficacy of lemborexant.","authors":"Charles M Morin, Alex Desautels, Dinesh Kumar, Kate Pinner, Barbara Ramos, Margaret Moline","doi":"10.1080/00325481.2025.2609392","DOIUrl":"10.1080/00325481.2025.2609392","url":null,"abstract":"<p><strong>Objectives: </strong>To review the efficacy of lemborexant (LEM), a dual orexin-receptor antagonist approved in multiple countries for treatment of insomnia in adults, by assessing the consistency of the available LEM objective and subjective evidence.</p><p><strong>Methods: </strong>Data from 2 pivotal phase 3, randomized, double-blind, parallel-group, placebo (PBO)-controlled studies are reviewed. Study 304 (1-month) and Study 303 (12-months; only first 6 months included here) evaluated the efficacy/safety of LEM 5 mg (LEM5) and LEM 10 mg (LEM10) in adults with insomnia disorder. Objective sleep onset (latency to persistent sleep [LPS]) and sleep maintenance (wake after sleep onset [WASO] and total sleep time [TST]) were assessed with polysomnography in Study 304. Subjective sleep onset latency (sSOL) and sleep maintenance (sWASO and sTST) were assessed with sleep diaries in both studies. Other patient-reported efficacy measures included Insomnia Severity Index-total score (ISI-TS), ISI-daytime functioning (ISI-DF), Fatigue Severity Scale (FSS), and Patient Global Impression-Insomnia (PGI-I).</p><p><strong>Results: </strong>Compared with PBO, significantly larger decreases (improvements) from baseline in LPS, sSOL, WASO, and sWASO and significantly larger increases (improvements) from baseline in TST and sTST were observed within the first week of LEM treatment (as early as within the first 1-2 nights) and were sustained throughout the treatment period (1-6 months) (all <i>p</i> < 0.05, except for sWASO at Month 1). These improvements aligned with significantly larger decreases (improvements) from baseline in ISI-TS, ISI-DF, and PGI-I (all <i>p</i> < 0.05). Significantly larger decreases (improvement) from baseline in FSS scores were observed at 3 and 6 months (both <i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>LEM showed concordance in its ability to improve objective and subjective measures of nighttime sleep, as well as daytime functioning and patient perception of nighttime sleep. These findings demonstrate that LEM is effective both objectively and from the patient's perspective, supporting LEM as a valuable treatment option for adults with insomnia.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"756-765"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145937007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-12-30DOI: 10.1080/00325481.2025.2609382
Khaled Seetan, Almu'atasim Khamees, Raghad Yousef Yassin, Saleh A Ba-Shammakh, Amir Majdi Moh'd
Objectives: Tinea capitis is one of the most common fungal infections in children around the world. However, the relationship between nutrition and the risk of infection, as well as treatment outcomes, has not been thoroughly studied. This study aimed to explore the relationship between certain micronutrient deficiencies and the occurrence, severity, and treatment response of tinea capitis in children.
Methods: This prospective cohort study included 280 children aged 2-12 years, with 140 confirmed cases of tinea capitis and 140 matched controls from three clinical locations. Detailed nutritional assessments included growth measurements and lab tests for zinc, iron, vitamin D, and protein-energy levels. The cases received standard antifungal treatment and were monitored for 6 months to evaluate treatment results. We employed multivariate analyses to identify relationships between nutritional factors and the occurrence, severity, and treatment outcomes of the disease.
Results: Even after controlling for other variables, zinc deficiency (OR = 2.87, 95% CI [1.71, 4.84], p < 0.001) and vitamin D deficiency (OR = 2.11, 95% CI [1.25, 3.58], p = 0.005) were found to increase the risk of tinea capitis independently. The symptoms and outcomes of treatment were worse in children with multiple nutritional deficiencies. At 8 weeks, children with nutritional deficiencies had a significantly lower rate of clinical cure (44.2%) than those without (71.4%, p < 0.001). The relationship between treatment response and socioeconomic status was significantly influenced by nutritional status.
Conclusions: Low levels of certain micronutrients, especially zinc and vitamin D, are key risk factors for children developing tinea capitis and not responding well to treatment. These findings suggest the potential benefits of integrated nutritional assessment and focused supplementation strategies, which should be evaluated in future interventional trials for pediatric tinea capitis, especially in resource-limited settings.
目的:头癣是世界上儿童最常见的真菌感染之一。然而,营养与感染风险以及治疗结果之间的关系尚未得到彻底研究。本研究旨在探讨某些微量营养素缺乏与儿童头癣的发生、严重程度和治疗反应之间的关系。方法:这项前瞻性队列研究包括280名2-12岁的儿童,140例确诊的头癣病例和140例匹配的对照组,来自三个临床地点。详细的营养评估包括生长测量和锌、铁、维生素D和蛋白质能量水平的实验室测试。病例接受标准抗真菌治疗,并监测6个月以评估治疗效果。我们采用多变量分析来确定营养因素与疾病的发生、严重程度和治疗结果之间的关系。结果:即使在控制了其他变量后,锌缺乏(OR = 2.87, 95% CI [1.71, 4.84], p = 0.005)仍可独立增加头癣的发生风险。多重营养缺乏症患儿的症状和治疗效果更差。8周时,营养缺乏儿童的临床治愈率(44.2%)明显低于无营养缺乏儿童的临床治愈率(71.4%)。结论:某些微量营养素水平低,特别是锌和维生素D水平低,是儿童发生头癣且治疗效果不佳的关键危险因素。这些发现表明,综合营养评估和重点补充策略的潜在益处,应在未来对儿童头癣的介入试验中进行评估,特别是在资源有限的情况下。
{"title":"Nutritional deficiencies as risk factors for incidence and treatment response of tinea capitis in children: a prospective clinical cohort study.","authors":"Khaled Seetan, Almu'atasim Khamees, Raghad Yousef Yassin, Saleh A Ba-Shammakh, Amir Majdi Moh'd","doi":"10.1080/00325481.2025.2609382","DOIUrl":"10.1080/00325481.2025.2609382","url":null,"abstract":"<p><strong>Objectives: </strong>Tinea capitis is one of the most common fungal infections in children around the world. However, the relationship between nutrition and the risk of infection, as well as treatment outcomes, has not been thoroughly studied. This study aimed to explore the relationship between certain micronutrient deficiencies and the occurrence, severity, and treatment response of tinea capitis in children.</p><p><strong>Methods: </strong>This prospective cohort study included 280 children aged 2-12 years, with 140 confirmed cases of tinea capitis and 140 matched controls from three clinical locations. Detailed nutritional assessments included growth measurements and lab tests for zinc, iron, vitamin D, and protein-energy levels. The cases received standard antifungal treatment and were monitored for 6 months to evaluate treatment results. We employed multivariate analyses to identify relationships between nutritional factors and the occurrence, severity, and treatment outcomes of the disease.</p><p><strong>Results: </strong>Even after controlling for other variables, zinc deficiency (OR = 2.87, 95% CI [1.71, 4.84], <i>p</i> < 0.001) and vitamin D deficiency (OR = 2.11, 95% CI [1.25, 3.58], <i>p</i> = 0.005) were found to increase the risk of tinea capitis independently. The symptoms and outcomes of treatment were worse in children with multiple nutritional deficiencies. At 8 weeks, children with nutritional deficiencies had a significantly lower rate of clinical cure (44.2%) than those without (71.4%, <i>p</i> < 0.001). The relationship between treatment response and socioeconomic status was significantly influenced by nutritional status.</p><p><strong>Conclusions: </strong>Low levels of certain micronutrients, especially zinc and vitamin D, are key risk factors for children developing tinea capitis and not responding well to treatment. These findings suggest the potential benefits of integrated nutritional assessment and focused supplementation strategies, which should be evaluated in future interventional trials for pediatric tinea capitis, especially in resource-limited settings.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"887-896"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145859857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-10-27DOI: 10.1080/00325481.2025.2580735
Xi Xia, Hongli Meng, Jianbo Li, Erying Shu, Miao Chen
Introduction: The effects of estrogen on arrhythmias are controversial. While animal studies suggest complex effects, the hypothesis that higher estrogen levels increase women's arrhythmia susceptibility has not yet been fully validated in human studies.
Case report: This case report describes a 30-year-old female patient who frequently experienced palpitations and was initially diagnosed with idiopathic ventricular arrhythmia. However, her symptoms were strongly correlated with her menstrual cycle. She experienced premature ventricular contractions (PVCs) 6 days before menstruation and 5 days before ovulation, which coincided with elevated estrogen levels. After other potential causes were ruled out, a diagnosis of hormone-induced PVCs was established. The patient was treated with a combination of estrogen and progestogen that not only alleviated her palpitations but also relieved her dysmenorrhea and menstrual irregularities. During a 5-month follow-up period, the patient reported no further palpitations.
Conclusion: This case provides clinical support of the hypothesis that elevated estrogen levels can increase vulnerability to ventricular arrhythmias in women. The influence of estrogen on arrhythmias may occur via a biphasic effect that potentially provides antiarrhythmic benefits during phases of low estrogen and increases the risk of arrhythmia during peak estrogen phases. Clinicians should consider hormone-related arrhythmias when young female patients present with palpitations that follow a cyclical pattern that is clearly linked to the menstrual cycle. Such cases warrant thorough history-taking and assessments of sex hormone levels. Hormonal regulation therapy could be an effective treatment strategy; however, its effectiveness and safety require careful evaluation.
{"title":"Estrogen-sensitive menstrual cycle-dependent premature ventricular contractions successfully treated with combined contraceptive therapy: a case report.","authors":"Xi Xia, Hongli Meng, Jianbo Li, Erying Shu, Miao Chen","doi":"10.1080/00325481.2025.2580735","DOIUrl":"10.1080/00325481.2025.2580735","url":null,"abstract":"<p><strong>Introduction: </strong>The effects of estrogen on arrhythmias are controversial. While animal studies suggest complex effects, the hypothesis that higher estrogen levels increase women's arrhythmia susceptibility has not yet been fully validated in human studies.</p><p><strong>Case report: </strong>This case report describes a 30-year-old female patient who frequently experienced palpitations and was initially diagnosed with idiopathic ventricular arrhythmia. However, her symptoms were strongly correlated with her menstrual cycle. She experienced premature ventricular contractions (PVCs) 6 days before menstruation and 5 days before ovulation, which coincided with elevated estrogen levels. After other potential causes were ruled out, a diagnosis of hormone-induced PVCs was established. The patient was treated with a combination of estrogen and progestogen that not only alleviated her palpitations but also relieved her dysmenorrhea and menstrual irregularities. During a 5-month follow-up period, the patient reported no further palpitations.</p><p><strong>Conclusion: </strong>This case provides clinical support of the hypothesis that elevated estrogen levels can increase vulnerability to ventricular arrhythmias in women. The influence of estrogen on arrhythmias may occur via a biphasic effect that potentially provides antiarrhythmic benefits during phases of low estrogen and increases the risk of arrhythmia during peak estrogen phases. Clinicians should consider hormone-related arrhythmias when young female patients present with palpitations that follow a cyclical pattern that is clearly linked to the menstrual cycle. Such cases warrant thorough history-taking and assessments of sex hormone levels. Hormonal regulation therapy could be an effective treatment strategy; however, its effectiveness and safety require careful evaluation.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"719-723"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145369435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-12-09DOI: 10.1080/00325481.2025.2601348
Duygu Aydın, Ayla Günlemez
Introduction: Hyperkalemia is a critical electrolyte imbalance in neonatal intensive care unit (NICU), linked to increased mortality. This study aimed to determine the prevalence, etiological factors, and clinical outcomes of hyperkalemia in neonates admitted to the NICU over a 10-year period, with a specific focus on differentiating actual hyperkalemia from pseudohyperkalemia according to gestational age - based thresholds.
Materials and methods: Data from NICU admissions over 10 years were analyzed. Hyperkalemia was defined as potassium levels ≥6 mmol/L in term neonates and >6.5 mmol/L in preterm. Cases of pseudohyperkalemia, primary etiology, and mortality were assessed.
Results: Among 5997 admissions, hyperkalemia was observed in 4.9% of cases, while true hyperkalemia was confirmed in 1.6%. Pseudohyperkalemia was the most common type. Actual hyperkalemia was more frequent in term neonates (p = 0.016). Acute kidney injury (AKI) was identified in 43.6% of cases. In term neonates, the most common causes were asphyxia, AKI, and congenital adrenal hyperplasia, whereas in preterms, they were AKI, hypoxia, and hemorrhage. A negative correlation was found between Apgar scores and potassium levels (p < 0.001). Mortality rates were 7.2% in neonates without actual hyperkalemia and 37.2% in those with it.
Conclusion: Hyperkalemia is a common and serious condition in NICUs, requiring prompt differentiation of pseudohyperkalemia from actual hyperkalemia. Given its high mortality risk, rapid etiology-specific treatment and potassium-lowering therapies are essential for managing actual hyperkalemia.
{"title":"Hyperkalemia in the neonatal intensive care unit: actual or pseudohyperkalemia?","authors":"Duygu Aydın, Ayla Günlemez","doi":"10.1080/00325481.2025.2601348","DOIUrl":"10.1080/00325481.2025.2601348","url":null,"abstract":"<p><strong>Introduction: </strong>Hyperkalemia is a critical electrolyte imbalance in neonatal intensive care unit (NICU), linked to increased mortality. This study aimed to determine the prevalence, etiological factors, and clinical outcomes of hyperkalemia in neonates admitted to the NICU over a 10-year period, with a specific focus on differentiating actual hyperkalemia from pseudohyperkalemia according to gestational age - based thresholds.</p><p><strong>Materials and methods: </strong>Data from NICU admissions over 10 years were analyzed. Hyperkalemia was defined as potassium levels ≥6 mmol/L in term neonates and >6.5 mmol/L in preterm. Cases of pseudohyperkalemia, primary etiology, and mortality were assessed.</p><p><strong>Results: </strong>Among 5997 admissions, hyperkalemia was observed in 4.9% of cases, while true hyperkalemia was confirmed in 1.6%. Pseudohyperkalemia was the most common type. Actual hyperkalemia was more frequent in term neonates (<i>p</i> = 0.016). Acute kidney injury (AKI) was identified in 43.6% of cases. In term neonates, the most common causes were asphyxia, AKI, and congenital adrenal hyperplasia, whereas in preterms, they were AKI, hypoxia, and hemorrhage. A negative correlation was found between Apgar scores and potassium levels (<i>p</i> < 0.001). Mortality rates were 7.2% in neonates without actual hyperkalemia and 37.2% in those with it.</p><p><strong>Conclusion: </strong>Hyperkalemia is a common and serious condition in NICUs, requiring prompt differentiation of pseudohyperkalemia from actual hyperkalemia. Given its high mortality risk, rapid etiology-specific treatment and potassium-lowering therapies are essential for managing actual hyperkalemia.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"814-819"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145717155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-12-28DOI: 10.1080/00325481.2025.2609372
Wenrui Shi, Yangbin Shi, Jieun Park, Shaohui Wu
Background: Life's Crucial 9 (LC9) was recently proposed by adding depression to Life's Essential 8 (LE8) to better predict future health risks. However, its superiority over LE8 in predicting outcomes in individuals with prediabetes or diabetes remains unclear.
Methods: We analyzed data from 7044 individuals with diabetes or prediabetes from the National Health and Nutrition Examination Survey (NHANES). LC9 was calculated as the mean of the LE8 score and a depression score, representing psychological health. We used Cox regression to assess the association of these scores with all-cause and cardiovascular mortality. Receiver operating characteristic curves and reclassification analyses were employed to compare predictive performance.
Results: During a median follow-up of 6.58 years (IQR: 4.67-8.75), 782 participants (11.10%) died, with 243 (3.45%) from cardiovascular causes. Each 10-point increase in LE8 score was associated with a hazard ratio (HR) of 0.807 (95% CI: 0.733-0.888) for all-cause mortality, while LC9 showed a stronger association with HR 0.750 (95% CI: 0.673-0.835). LC9 significantly improved the prediction of all-cause mortality (AUC 0.574 vs. 0.589, p = 0.021), supported by reclassification indices (p < 0.001). However, for cardiovascular mortality, both scores showed similar HRs, and no improvement was observed with LC9.
Conclusions: Incorporating depression into LE8 could improve the prediction of all-cause mortality in diabetic and prediabetic populations. Given its practicality and low cost, routine depression screening may offer a feasible strategy to enhance risk stratification in primary care settings.
{"title":"Enhancing mortality prediction by incorporating depression into life's essential 8 in diabetic and prediabetic populations: evidence from NHANES 2009-2016.","authors":"Wenrui Shi, Yangbin Shi, Jieun Park, Shaohui Wu","doi":"10.1080/00325481.2025.2609372","DOIUrl":"10.1080/00325481.2025.2609372","url":null,"abstract":"<p><strong>Background: </strong>Life's Crucial 9 (LC9) was recently proposed by adding depression to Life's Essential 8 (LE8) to better predict future health risks. However, its superiority over LE8 in predicting outcomes in individuals with prediabetes or diabetes remains unclear.</p><p><strong>Methods: </strong>We analyzed data from 7044 individuals with diabetes or prediabetes from the National Health and Nutrition Examination Survey (NHANES). LC9 was calculated as the mean of the LE8 score and a depression score, representing psychological health. We used Cox regression to assess the association of these scores with all-cause and cardiovascular mortality. Receiver operating characteristic curves and reclassification analyses were employed to compare predictive performance.</p><p><strong>Results: </strong>During a median follow-up of 6.58 years (IQR: 4.67-8.75), 782 participants (11.10%) died, with 243 (3.45%) from cardiovascular causes. Each 10-point increase in LE8 score was associated with a hazard ratio (HR) of 0.807 (95% CI: 0.733-0.888) for all-cause mortality, while LC9 showed a stronger association with HR 0.750 (95% CI: 0.673-0.835). LC9 significantly improved the prediction of all-cause mortality (AUC 0.574 vs. 0.589, <i>p</i> = 0.021), supported by reclassification indices (<i>p</i> < 0.001). However, for cardiovascular mortality, both scores showed similar HRs, and no improvement was observed with LC9.</p><p><strong>Conclusions: </strong>Incorporating depression into LE8 could improve the prediction of all-cause mortality in diabetic and prediabetic populations. Given its practicality and low cost, routine depression screening may offer a feasible strategy to enhance risk stratification in primary care settings.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"876-886"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145852099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-12-17DOI: 10.1080/00325481.2025.2604332
Weizheng Huang, Jiaqi Wei, Yujiao Wu, Chengzi Huang, Yaling Li, Jun Li
Objective: To identify key risk factors associated with mortality in necrotizing fasciitis (NF) and provide clinicians with evidence-based guidance for risk stratification and management.
Methods: A systematic review and meta-analysis was conducted. PubMed, Embase, Web of Science, Cochrane Library, and ProQuest were searched from inception to 19 May 2023, with an update on 31 May 2025. Cohort studies reporting adjusted risk estimates for NF-related mortality were included. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.
Results: Of 30,563 identified articles, 14 studies involving 26,242 patients were included. The strongest predictors of NF mortality were advanced age (odds ratio [OR] 1.160, 95% CI 1.100-1.223), cardiopathy (OR 2.210, 95% CI 1.274-3.833), elevated creatinine (OR 2.200, 95% CI 1.127-4.294), and Clostridium infection (OR 6.422, 95% CI 2.171-19.003). Race appeared protective, particularly among Black patients (OR 0.780, 95% CI 0.645-0.943). No significant associations were found for gender, pneumopathy, hepatopathy, nephropathy, diabetes, malignancy, or several laboratory and microbial factors.
Conclusions: Advanced age, cardiopathy, elevated creatinine, and Clostridium infection are significant mortality risk factors in NF. Race may have a protective effect. Further research is warranted to clarify the roles of other clinical and laboratory variables.
目的:探讨与坏死性筋膜炎(NF)死亡率相关的关键危险因素,为临床医生进行风险分层和管理提供循证指导。方法:进行系统综述和荟萃分析。PubMed, Embase, Web of Science, Cochrane Library和ProQuest从成立到2023年5月19日进行了检索,并于2025年5月31日进行了更新。纳入了报告nf相关死亡率调整风险估计值的队列研究。计算合并优势比(ORs)和95%置信区间(ci)。结果:在30,563篇确定的文章中,纳入了14项研究,涉及26,242例患者。NF死亡率的最强预测因子是高龄(比值比[OR] 1.160, 95% CI 1.100-1.223)、心脏病(OR 2.210, 95% CI 1.274-3.833)、肌酐升高(OR 2.200, 95% CI 1.127-4.294)和梭状芽胞杆菌感染(OR 6.422, 95% CI 2.171-19.003)。种族表现出保护作用,尤其是黑人患者(OR 0.780, 95% CI 0.645-0.943)。性别、肺病、肝病、肾病、糖尿病、恶性肿瘤或一些实验室和微生物因素未发现显著相关性。结论:高龄、心脏病、肌酐升高和梭状芽胞杆菌感染是NF的重要死亡危险因素。种族可能有保护作用。进一步的研究是必要的,以澄清其他临床和实验室变量的作用。
{"title":"Mortality risk factors among patients with necrotizing fasciitis: a systematic review and meta-analysis of cohort studies.","authors":"Weizheng Huang, Jiaqi Wei, Yujiao Wu, Chengzi Huang, Yaling Li, Jun Li","doi":"10.1080/00325481.2025.2604332","DOIUrl":"10.1080/00325481.2025.2604332","url":null,"abstract":"<p><strong>Objective: </strong>To identify key risk factors associated with mortality in necrotizing fasciitis (NF) and provide clinicians with evidence-based guidance for risk stratification and management.</p><p><strong>Methods: </strong>A systematic review and meta-analysis was conducted. PubMed, Embase, Web of Science, Cochrane Library, and ProQuest were searched from inception to 19 May 2023, with an update on 31 May 2025. Cohort studies reporting adjusted risk estimates for NF-related mortality were included. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.</p><p><strong>Results: </strong>Of 30,563 identified articles, 14 studies involving 26,242 patients were included. The strongest predictors of NF mortality were advanced age (odds ratio [OR] 1.160, 95% CI 1.100-1.223), cardiopathy (OR 2.210, 95% CI 1.274-3.833), elevated creatinine (OR 2.200, 95% CI 1.127-4.294), and <i>Clostridium</i> infection (OR 6.422, 95% CI 2.171-19.003). Race appeared protective, particularly among Black patients (OR 0.780, 95% CI 0.645-0.943). No significant associations were found for gender, pneumopathy, hepatopathy, nephropathy, diabetes, malignancy, or several laboratory and microbial factors.</p><p><strong>Conclusions: </strong>Advanced age, cardiopathy, elevated creatinine, and <i>Clostridium</i> infection are significant mortality risk factors in NF. Race may have a protective effect. Further research is warranted to clarify the roles of other clinical and laboratory variables.</p>","PeriodicalId":94176,"journal":{"name":"Postgraduate medicine","volume":" ","pages":"850-856"},"PeriodicalIF":2.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145770352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}